Using a Clinical Decision Support System to Improve Anticoagulation in Patients with Nonvalve Atrial Fibrillation in China’s Primary Care Settings: A Feasibility Study
Table 2
Factors associated with the guideline-directed antithrombotic treatment of subjects.
No.&/n
Crude OR (95% CI)
Adjusted OR@(95% CI)
Group (software/control)
40/12
4.872 (1.873–12.672)
0.001
8.071 (2.570–25.344)
<0.001
Gender (male/female)
32/20
2.057 (0.841–5.031)
0.114
—
—
Age
—
1.001 (0.941–1.064)
0.979
—
—
Hypertension
49
3.025 (0.671–13.644)
0.150
—
—
Heart failure
5
0.745 (0.184–3.006)
0.679
—
—
Diabetes
17
0.741 (0.293–1.87)
0.526
—
—
Stroke/TIA/thromboembolism history
11
1.449 (0.453–4.637)
0.532
—
—
Antiplatelets or NSAIDs
12
0.300 (0.116–0.773)
0.013
0.165 (0.051–0.529)
0.002
CHA2DS2-VASc score (2/<2)
51/1
3.400 (0.296–39.104)
0.326
—
—
HAS-BLED score (3/<3)
26/26
0.684 (0.281–1.667)
0.404
—
—
&Number of subjects with guideline-directed antithrombotic treatment; @Adjusting for gender, age, hypertension, heart failure, diabetes, stroke/TIA/thromboembolism, CHA2DS2-VASc score, and HAS-BLED score. Values in bold were statistically significant.
